N.A. Roberts et al., “Rational Design of Peptide-Based HIV Protease Inhibitors” Science 248:358-362. |
T. Robbins et al., “HIV Protease Inhibitors: Their Anti-HIV Activity and Potential Role in Treatment” J. Acquired Immune Deficiency Syndromes 6(2):162-170 (1993). |
Communications to the Editor, “Intriguing Structure—Activity Relations Underlie the Potent Inhibition of HIV Protease by Norstatine-Based Peptides” J. Med. Chem. 35:1318-1320 (1992). |
Baldwin et al. (1995), “Structure of HIV-1 Protease With KNI-272, A Tight-Binding Transition-State Analog Containing Allophenylnorstatine,” 3 Structure 581-590. |
Kiso (1995), “Design and Synthesis of HIV Protease Inhibitors Containing Allophenylnorstatine As A Transition-State Mimic,” Aspartic Proteinases Structure, Function, Biology and Biomedical Implications, Ed. Kenji Takahashi, Plenum Press, NY, pp. 413-423. |
Gulnik et. al. (1995), “Kinetic Characterization and Cross-Resistance Patterns of HIV-1 Protease Mutant Selected under Drug Pressuer,” Biochemistry, vol. 34, No. 29, 9282-9287. |
Kageyama et al. (1993), “In Vitro Anti-Human Immunodeficiency Virus (HIV) Activities of Transition State Mimetic HIV Protease Inhibitors Containing Allophenylnorstatine,” 37 Antimicrob. Agents & Chemo. 4:810-817. |
Humphrey et al. (1997), “Removal of Human Immunodeficiency Virus Type I (HIV-1) Protease Inhibitors From Preparations of Immature HIV-1 Virions Does Not Result in an Increase in Infectivity or the Appearance of Mature Morphology,” 41 Antimicrob. Agents & Chemo. 5:1017-1023. |
Uchida et al. (1997), “HIV-1 Protease Does Not Play A Critical Role In The Early Stages of HIV-1 Infection,” 36 Antiviral Research 107-113. |
Fahey et al., “Status of Immune-Based Therapies In HIV Infection And AIDS,” Clin. Exp. Immunol., 88:1-5 (1992). |
Fox, J.L., “No Winners Against AIDS,” Bio/Technology, 12:128 (Feb., 1994). |
Haynes et al., “Update On The Issues Of HIV Vaccine Development,” Ann. Med., 28:39-41 (1996). |
Ashorn et al. (1990), “An Inhibitor of the Protease Blocks Maturation of Human and Simian Immunodeficiency Viruses and Spread of Infection,” 87 Proc. Natl. Acad. Sci. USA 7472-7476. |
Debouck et al. (1990), “Human Immunodeficiency Virus Protease: A Target For AIDS Therapy,” 21 Drug Dev. Res. 1-17. |
Meek et al. (1990), “Inhibition of HIV-1 Protease In Infected T-lymphocytes by Synthetic Peptide Analogues,” 343 Nature 90-92. |
McCune et al. (1990), “Suppression of HIV Infection in AZT-Treated SCID-hu Mice,” 247 Science 564-566. |
Kaneshima et al. (1991), “Human Immunodeficiency Virus Infection of Human Lymph Nodes in the SCID-hu Mouse,” 88 Proc. Natl. Acad. Sci. USA 4523-4527. |
McCune et al. (1991), “Preclinical Evaluation of Human Hematolymphoid Function in the SCID-hu Mouse,” 124 Immunolog. Rev. 45-62. |
Mimoto et al. (1991), “Rational Design and Synthesis of a Novel Class of Active Site-Targeted HIV Protease Inhibitors Containing a Hydroxymethylcarbonyl Isostere. Use of Phenylnorstatine or Allophenylnorstatine As A Transition-State Mimic,” 39 Chem. Pharm. Bull. 9:2465-2467. |
Romero et al. (1991), “Nonnucleoside Reverse Transcriptase Inhibitors That Potently and Specifically Block Human Immunodeficiency Virus Type 1 Replication,” 88 Proc. Natl. Acad. Sci. USA 8806-8810. |
Shih et al. (1991), “Postexposure Prophylaxis With Zidovudine Suppresses Human Immunodeficiency Virus Type 1 Infection in SCID-hum Mice in a Time-Dependent Manner,” 163 J. Infect. Dis. 625-627. |
Kageyama et al. (1992), “In Vitro Inhibition of Human Immunodeficiency Virus (HIV) Type 1 Replication by C2 Symmetry-Based HIV Protease Inhibitors As Single Agents or in Combination,” 36 Antimicrob. Agents Chem. 5:926-931. |
Meek (1992), “Inhibitors of HIV-1 Protease,” 6 J. Enzyme Inhib. 65-98. |
Mimoto et al. (1992), “Kynostatin (KNI)-227 and -272, Highly Potent Anti-HIV Agents: Conformationally Constrained Tripeptide Inhibitors of HIV Protease Containing Allophenylnorstatine,” 40 Chem. Pharm. Bull. *:2251-2253. |
“Japan Energy To Test AIDS Drug In Britain,” Press Release Dec. 4, 1995; Jiji Press Ticker Service, Tokyo, Japan. |
“Japan Energy Starts Clinical Testing of AIDS Drug In UK,” Press Release Dec. 5, 1995; Jiji Press Ticker Service, Tokyo, Japan. |
“Anti-AIDS Drug Test Go To Britain,” Press Release Dec. 5, 1995; Japan Times, Tokyo, Japan. |
Ussery et al. (1995), “In Vivo Antibacterial of the Protease Inhibitors KNI-272 in the HIV-Infected HuPBMC-SCID Mouse Model,” 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, Annual Meeting of The American Society For Microbiology, Abstract No. 125, p. 227. |
Abstract, “XI International Conference on AIDS, Vancouver, Jul. 7-12, 1996,” vol. 1, p. 77 (Ref. No. Mo.B. 1132); published Jul. 6, 1996; presented Jul. 8, 1996. |
Caplus AN 1993: 22632, 1993. |